CRG

CRG is a healthcare-focused investment firm established in 2003, headquartered in Boulder, Colorado. The company specializes in providing growth capital financing solutions to the global healthcare industry, targeting investments primarily in FDA-approved biopharmaceutical assets, medical devices, diagnostics, and healthcare services. CRG utilizes innovative financing structures such as royalty bonds, structured debt, and revenue interests, facilitating investments ranging from $20 million to $200 million. By collaborating directly with healthcare companies, research institutions, and inventors, CRG offers customized capital solutions that serve as attractive alternatives to conventional equity and debt financing. The company aims to support healthcare organizations in funding pipeline development, making acquisitions, and expanding into new markets while minimizing dilution of ownership. With a unique expertise in structuring various financing mechanisms, CRG is well-positioned to meet diverse financing needs within the healthcare sector, ultimately delivering superior risk-adjusted returns to its investors, which include pension funds, insurance companies, and other institutional investors.

Grobe CPA, Courtney

CFO

Scott Li

Managing Director

59 past transactions

Calyxo

Series C in 2022
Calyxo, Inc. is a medical device company established in 2016 that specializes in innovative solutions for patients suffering from kidney stones, a condition that significantly impacts healthcare resources. The company has developed a vacuum-assisted retrieval device that allows for the efficient removal of multiple kidney stone fragments in a single insertion, offering a quick and effective procedure for healthcare providers. This device aims to enhance patient outcomes by ensuring a stone-free result, thereby streamlining the treatment process. Calyxo is led by a team of experienced professionals with a strong background in urology, united by a commitment to improving kidney stone care through technological advancements.

Treace Medical Concepts

Debt Financing in 2020
Treace Medical Concepts, Inc. is a medical device company based in Ponte Vedra Beach, Florida, that specializes in the design, manufacture, and marketing of innovative surgical solutions for foot and ankle physicians. Founded in 2014, the company focuses on advancing the standard of care for bunion deformities through its patented Lapiplasty 3D Bunion Correction procedure. This procedure aims to correct all planes of the bunion deformity effectively, addressing its root cause and facilitating quicker recovery for patients. Additionally, Treace Medical Concepts offers the ProHarvester, a percutaneous autograft extraction system that allows for minimally invasive harvesting of autograft bone and bone marrow. The company operates within the expanding $1.1 billion U.S. market for foot and ankle surgical products, with a commitment to improving patient outcomes and reducing healthcare costs.

Aerin Medical

Debt Financing in 2019
Aerin Medical Inc. is a health technology company based in Sunnyvale, California, specializing in non-invasive treatment solutions for nasal breathing disorders. Established in 2011, the company has developed therapeutic devices that utilize low-power radiofrequency energy to remodel nasal soft tissues, effectively addressing the underlying causes of nasal congestion. Its primary products include the VivAer procedure for nasal airway obstruction and the RhinAer procedure for chronic rhinitis, both of which employ proprietary temperature-controlled technology. These solutions offer ENT physicians appealing alternatives to invasive surgery, allowing them to treat patients under local anesthesia with minimal to no downtime. Aerin Medical aims to meet the unmet needs of individuals suffering from chronic nasal airway conditions through its innovative and office-friendly product offerings.

EyePoint Pharmaceuticals

Debt Financing in 2019
EyePoint Pharmaceuticals is a specialty biopharmaceutical company focused on developing and commercializing ophthalmic products for the treatment of eye diseases, primarily in the United States and Europe. The company offers several FDA-approved products, including ILUVIEN for diabetic macular edema, YUTIQ for chronic non-infectious uveitis, DEXYCU for post-operative ocular inflammation, and Retisert for posterior segment uveitis. EyePoint is also advancing its pipeline with EYP-1901, a bioerodible implant targeting wet age-related macular degeneration and related conditions, as well as YUTIQ50 for uveitis. The company utilizes its proprietary Durasert and Verisome technology platforms to create sustained-release drug delivery systems. EyePoint has established strategic collaborations with various organizations and engages in a commercial alliance for the promotion of its products. Founded in 1987 and headquartered in Watertown, Massachusetts, EyePoint was previously known as pSivida Corp.

Mid-Atlantic Dental Partners

Venture Round in 2019
Mid-Atlantic Dental Partners is a growing regional dental support organization (DSO) founded on the principle that high quality dental care requires a three-way partnership between the patient, the dentist and their support organization. An effective DSO must enable the dental team to focus all their attention on their patients while taking responsibility for all of the practices’ non-clinical activities. These services include billing, collections, scheduling, clinical data analytics, group purchasing, marketing and assisting each practice in recruiting dental professionals. Mid-Atlantic Dental Partners is also committed to assuring each dentist clinical autonomy while improving the lifestyle of its dental partners and their staffs.

HNI Healthcare

Private Equity Round in 2018
HNI Healthcare (formerly Hospitalists Now) is a technology-enabled physician practice management company focused on the delivery of full-service facility-based physician programs to improve the quality of patient care. The Company’s physicians, processes and technologies enable healthcare facilities to improve key quality and performance metrics through a more clinically integrated care model.

EndoGastric Solutions

Series I in 2018
EndoGastric Solutions, Inc. is a medical device company specializing in innovative surgical technologies aimed at treating gastrointestinal diseases, particularly gastroesophageal reflux disease (GERD). Founded in 2002 and headquartered in Redmond, Washington, with an additional office in San Mateo, California, the company develops and manufactures natural orifice surgical products. Its flagship technology, EsophyX, facilitates transoral reconstructive surgery, while the EsophyX Z device is specifically designed for the transoral incisionless fundoplication procedure. Additionally, EndoGastric Solutions offers SerosaFuse Fasteners, a non-resorbable polypropylene product that provides strength comparable to traditional sutures. The company also supports surgeons through training courses and a range of consultative services, including pre-authorization and medical review.

Fast Pace Health

Private Equity Round in 2018
Fast Pace Health provides primary and urgent care to the communities they serve. They provide treatments for minor injuries, skin conditions, and diagnostics. Their services include behavioral health, dermatology care, occupational health, physical therapy, orthopedic care, and telehealth services.
Dynavax Technologies Corporation is a biopharmaceutical company based in Emeryville, California, focused on developing and commercializing innovative vaccines. The company's primary product, HEPLISAV-B, is an approved hepatitis B vaccine designed to prevent infection from all known subtypes of the virus in adults aged 18 and older. Dynavax is also advancing its proprietary CpG 1018 adjuvant to enhance vaccine efficacy and is engaged in various collaborations aimed at developing adjuvanted vaccines for COVID-19, pertussis, and universal influenza. In addition to its commercial efforts, Dynavax is involved in research partnerships with organizations such as Clover Biopharmaceuticals, the University of Queensland, and the Coalition for Epidemic Preparedness Innovations to create new vaccine candidates. The company was originally founded in 1996 as Double Helix Corporation and rebranded to its current name in September 1996.
Synergy Pharmaceuticals Inc., headquartered in New York, NY with laboratories in Doylestown, PA, is a biopharmaceutical company focused on the research and development of novel therapies for the treatment of chronic idiopathic constipation, irritable bowel syndrome with constipation and other difficult-to-treat gastrointestinal (GI) conditions. Synergy’s lead drug, plecanatide, and next-generation candidate, SP-333, are proprietary analogs of the natural human GI hormone, uroguanylin, and members of the new class of guanylate cyclase-C (“GC-C”) agonists.

Silk Road Medical

Series C in 2017
Silk Road Medical, Inc. is a medical device company based in Sunnyvale, California, specializing in the treatment of carotid artery disease through its innovative transcarotid artery revascularization (TCAR) approach. Founded in 2007, the company develops and manufactures minimally invasive devices aimed at reducing the risk of stroke and improving patient outcomes. Its product portfolio includes the ENROUTE Transcarotid Neuroprotection System, which facilitates direct access to the common carotid artery while ensuring temporary blood flow reversal to protect the brain, and the ENROUTE Transcarotid Stent System, a self-expanding stent supported by clinical data on safety outcomes. Additionally, the ENHANCE Transcarotid Peripheral Access Kit and the ENROUTE 0.014 Guidewire are designed to aid in gaining access and delivering interventional devices effectively. Silk Road Medical aims to establish TCAR as the standard of care for carotid artery disease treatment.
Strongbridge Biopharma plc is a commercial-stage biopharmaceutical company dedicated to developing and commercializing therapies for rare diseases with significant unmet medical needs. The company markets Keveyis, an oral carbonic anhydrase inhibitor used to treat various forms of primary periodic paralysis in the United States. Its clinical pipeline includes Recorlev, a cortisol synthesis inhibitor currently in Phase III trials for endogenous Cushing's syndrome, and Veldoreotide, a somatostatin analog that has completed Phase II trials for acromegaly. Founded in 1996 and based in Trevose, Pennsylvania, Strongbridge Biopharma aims to build its portfolio around rare endocrine disorders and plans to utilize a focused sales strategy to reach its target markets. The company is also actively seeking to in-license or acquire complementary products to enhance its rare disease franchise.
Strongbridge Biopharma plc is a commercial-stage biopharmaceutical company dedicated to developing and commercializing therapies for rare diseases with significant unmet medical needs. The company markets Keveyis, an oral carbonic anhydrase inhibitor used to treat various forms of primary periodic paralysis in the United States. Its clinical pipeline includes Recorlev, a cortisol synthesis inhibitor currently in Phase III trials for endogenous Cushing's syndrome, and Veldoreotide, a somatostatin analog that has completed Phase II trials for acromegaly. Founded in 1996 and based in Trevose, Pennsylvania, Strongbridge Biopharma aims to build its portfolio around rare endocrine disorders and plans to utilize a focused sales strategy to reach its target markets. The company is also actively seeking to in-license or acquire complementary products to enhance its rare disease franchise.

Earlens

Debt Financing in 2017
Earlens is a medical technology company focused on improving the hearing experience for individuals with hearing loss. It has created the Earlens Contact Hearing Solution, a unique device that directly stimulates the eardrum using a small lens, replicating the natural hearing process. Unlike conventional hearing aids that amplify sound, the Earlens solution delivers sound directly to the eardrum, providing superior sound quality and a broader bandwidth. This innovative, non-surgical approach allows for automatic adjustments in challenging listening environments while minimizing feedback. The technology received FDA clearance in 2019 for its second generation, marking a significant advancement in hearing solutions aimed at enhancing the quality of life for those with hearing impairment.

Earlens

Series C in 2017
Earlens is a medical technology company focused on improving the hearing experience for individuals with hearing loss. It has created the Earlens Contact Hearing Solution, a unique device that directly stimulates the eardrum using a small lens, replicating the natural hearing process. Unlike conventional hearing aids that amplify sound, the Earlens solution delivers sound directly to the eardrum, providing superior sound quality and a broader bandwidth. This innovative, non-surgical approach allows for automatic adjustments in challenging listening environments while minimizing feedback. The technology received FDA clearance in 2019 for its second generation, marking a significant advancement in hearing solutions aimed at enhancing the quality of life for those with hearing impairment.

Viveve

Debt Financing in 2017
Viveve is a women's sexual health company that specializes in non-surgical treatments aimed at addressing issues related to vaginal looseness and loss of sensation, which can occur after childbirth. The company has developed the Viveve System, a medical technology that employs cryogen-cooled monopolar radiofrequency technology to restore collagen fibers that may have been overstretched or damaged during delivery. This system is designed for non-invasive treatments of vaginal laxity, sexual function enhancement, vaginal rejuvenation, and stress urinary incontinence. Founded in 2005 and based in Palo Alto, California, Viveve operates in multiple regions, including the United States, Asia Pacific, Canada, Europe, the Middle East, and Latin America, and markets its products for various surgical applications.
BioDelivery Sciences International, Inc. is a specialty pharmaceutical company focused on developing and commercializing products for pain management and addiction medicine. Headquartered in Raleigh, North Carolina, the company utilizes its proprietary BioErodible MucoAdhesive (BEMA) drug delivery technology, which features a small erodible polymer film designed for application to the buccal mucosa. Its product offerings include BELBUCA, a buprenorphine buccal film for chronic pain; BUNAVAIL, a buprenorphine and naloxone buccal film for opioid dependence; ONSOLIS, a fentanyl buccal soluble film for breakthrough cancer pain; and Symproic, which addresses opioid-induced constipation in adult patients with chronic non-cancer pain. Founded in 1997, BioDelivery Sciences is committed to addressing significant unmet medical needs through innovative therapeutic solutions.

Endoceutics

Debt Financing in 2017
Endoceutics is a biopharmaceutical company focused on women's health, particularly in the areas of hormone-sensitive cancer prevention and treatment. The company specializes in developing hormone therapies aimed at addressing breast cancer and endocrine-related disorders. Endoceutics is engaged in the clinical development, recording, and marketing of its products, which are at various stages of development. Its mission is to enhance the quality of life for women by advancing basic sciences, conducting clinical research, and commercializing effective treatments for menopausal issues and related health concerns.

Barricaid

Venture Round in 2016
Barricaid is a medical device company that focuses on developing innovative solutions to prevent repeat disc herniation in patients who have undergone back surgery. The company's flagship product is a bone-anchored implant designed to reduce the likelihood of reherniation and the need for reoperation in cases involving large annular defects. This implant physically blocks the annulus at the surgical defect, enhancing the surgical outcome for patients at high risk of complications after lumbar discectomy. Composed of a titanium alloy, the device securely anchors into the vertebral body, either caudally or cranially, ensuring stability and effectiveness. By addressing the challenges associated with post-surgical recovery, Barricaid aims to improve patient outcomes and reduce the incidence of further surgeries related to sciatica.

Hicuity Health

Debt Financing in 2016
Hicuity Health is a leading provider of high acuity telehealth services, delivering care to over 115 hospitals across 30 states on a continuous basis. The company focuses on acute care telemedicine, offering ICU programs and evidence-based protocols that utilize advanced telehealth technology. By connecting U.S. board-certified intensivists, nurses, and onsite clinicians with patients and their families, Hicuity Health enhances critical care delivery. The organization operates multiple dedicated tele-care delivery centers and emphasizes a proven implementation and client service approach, ultimately aiming to improve patient outcomes and support healthcare providers and institutions.

T2 Biosystems

Post in 2016
T2 Biosystems, Inc. is an in vitro diagnostics company focused on developing advanced diagnostic products for detecting pathogens and biomarkers. Utilizing its proprietary T2 Magnetic Resonance technology, the company offers rapid and accurate testing for various medical conditions directly from unpurified patient samples, including whole blood, plasma, and urine. Key products include the T2Dx Instrument for diagnosing sepsis and Lyme disease, the T2Candida Panel for identifying Candida species, and the T2Bacteria Panel for detecting bacterial pathogens linked to sepsis. Additionally, T2 Biosystems provides the T2Resistance Panel for identifying antibiotic resistance markers and is developing other diagnostic panels for multi-drug resistant pathogens and Lyme disease strains. The company collaborates with organizations like Canon U.S. Life Sciences and Allergan Sales to enhance its testing capabilities. Founded in 2006 and based in Lexington, Massachusetts, T2 Biosystems aims to improve patient care and reduce healthcare costs through its innovative diagnostic solutions.

Omeros

Post in 2016
Omeros Corporation is a Seattle-based biopharmaceutical company that focuses on discovering, developing, and commercializing small-molecule and protein therapeutics for a range of indications, including inflammation, complement-mediated diseases, and central nervous system disorders. The company is known for its commercial product, OMIDRIA, which is used during cataract surgery in the United States. Omeros has several clinical programs, with its lead candidate, Narsoplimab, in Phase III trials for conditions such as thrombotic microangiopathy and immunoglobulin A nephropathy, as well as Phase II trials for lupus nephritis. Other clinical programs include OMS405 for opioid and nicotine addiction and OMS527 for addiction and compulsive disorders. The company also has a robust pipeline of preclinical programs targeting various disorders, including MASP-3 for paroxysmal nocturnal hemoglobinuria and a GPCR platform aimed at treating a broad range of diseases. Omeros was incorporated in 1994 and remains dedicated to addressing significant unmet medical needs.

Access TeleCare

Debt Financing in 2016
Access TeleCare is a provider of acute care telemedicine and technology services aimed at hospitals, health systems, post-acute providers, and physician networks. The company specializes in a range of clinical specialties, including telecardiology, teleneurology, telepsychiatry, telepulmonology, telehospitalists, teleinfectious disease, and telematernal fetal medicine. By leveraging advanced technology, Access TeleCare facilitates virtual patient care, helping healthcare organizations develop sustainable telemedicine programs. Their comprehensive offerings enable healthcare providers to enhance patient access to specialized care and improve overall healthcare delivery.

Iroko Pharmaceuticals

Debt Financing in 2016
In the short period since Iroko was founded in 2007, we have assembled a portfolio of proven pharmaceuticals, especially prescription pain medicines. Our goal has been to bring new life to these trusted products—new geographic markets, new indications, and new benefits through further development enabled by new technology. We have already extended a distribution and sales network across more than 40 countries. And we have developed an industry-leading pipeline of nano-formulated lower-dose NSAIDs to address the need for new options in pain management. Experience. Marketed products. A global presence. Innovation. That’s Iroko. We’re an established company. And we’re hurrying to improve healthcare.

Cardiome Pharma

Post in 2016
Cardiome Pharma Corp. is a specialty biopharmaceutical company dedicated to the discovery, development and commercialization of new therapies that will improve the health of patients suffering from heart disease around the world. Cardiome has one marketed product, BRINAVESSTM (vernakalant IV), approved in Europe and other territories for the rapid conversion of recent onset atrial fibrillation to sinus rhythm in adults.

Valeritas

Venture Round in 2016
Valeritas Holdings, Inc. was a medical technology company focused on developing and commercializing innovative drug delivery solutions for patients with Type 2 diabetes. The company's primary product was the V-Go, a disposable insulin delivery device designed for continuous basal and on-demand bolus dosing, aimed at simplifying insulin management for users. Valeritas also worked on the V-Go Prefill, intended to streamline the device-filling process, and the V-Go SIM, which provided real-time tracking of insulin dosing. Founded in 2006 and headquartered in Bridgewater, New Jersey, Valeritas sold its products through third-party wholesalers and medical supply distributors. However, the company filed for Chapter 11 bankruptcy on June 30, 2020, ceasing operations.

Benvenue Medical

Debt Financing in 2016
Benvenue Medical, Inc. is a company specializing in the design, manufacture, and marketing of minimally invasive expandable implant systems for the treatment of spinal disorders, particularly vertebral compression fractures and degenerative disc diseases. Its key products include the Kiva treatment system, which addresses spinal fractures in the thoracic and lumbar regions, and the Blazer – C system, designed for pathological vertebral compression fractures. Additionally, the company offers the Luna 3D expandable interbody fusion system, suitable for various surgical approaches. Headquartered in Santa Clara, California, Benvenue Medical serves customers across the United States, Canada, Belgium, France, and Germany. Founded in 2004, the company is committed to providing innovative solutions that enhance patient outcomes and restore spinal alignment.

Realeve

Debt Financing in 2016
Autonomic Technologies, Inc. is a medical device company that specializes in developing and commercializing innovative therapies for autonomic disorders, with a particular emphasis on severe headaches. Founded in 2007 and headquartered in Mountain View, California, the company has additional offices in Germany and Switzerland. Its flagship product, the ATI Neurostimulation System, is a miniaturized, battery-less microstimulator designed to deliver low-level energy directly to the sphenopalatine ganglion (SPG) to effectively treat chronic cluster headaches. This technology aims to set a new standard in the management of severe headaches and migraines, providing patients with a safe and effective treatment option.

EndoGastric Solutions

Venture Round in 2015
EndoGastric Solutions, Inc. is a medical device company specializing in innovative surgical technologies aimed at treating gastrointestinal diseases, particularly gastroesophageal reflux disease (GERD). Founded in 2002 and headquartered in Redmond, Washington, with an additional office in San Mateo, California, the company develops and manufactures natural orifice surgical products. Its flagship technology, EsophyX, facilitates transoral reconstructive surgery, while the EsophyX Z device is specifically designed for the transoral incisionless fundoplication procedure. Additionally, EndoGastric Solutions offers SerosaFuse Fasteners, a non-resorbable polypropylene product that provides strength comparable to traditional sutures. The company also supports surgeons through training courses and a range of consultative services, including pre-authorization and medical review.

Silk Road Medical

Venture Round in 2015
Silk Road Medical, Inc. is a medical device company based in Sunnyvale, California, specializing in the treatment of carotid artery disease through its innovative transcarotid artery revascularization (TCAR) approach. Founded in 2007, the company develops and manufactures minimally invasive devices aimed at reducing the risk of stroke and improving patient outcomes. Its product portfolio includes the ENROUTE Transcarotid Neuroprotection System, which facilitates direct access to the common carotid artery while ensuring temporary blood flow reversal to protect the brain, and the ENROUTE Transcarotid Stent System, a self-expanding stent supported by clinical data on safety outcomes. Additionally, the ENHANCE Transcarotid Peripheral Access Kit and the ENROUTE 0.014 Guidewire are designed to aid in gaining access and delivering interventional devices effectively. Silk Road Medical aims to establish TCAR as the standard of care for carotid artery disease treatment.

GenomeDx Biosciences

Debt Financing in 2015
GenomeDx discovers, develops, and commercializes genomic-based laboratory tests for the personalized medicine revolution in cancer care. In partnership with physicians and scientists from leading academic medicine institutions, our mission is to bring cost-effective and high-resolution genomics for routine clinical use in cancer medicine.

Avinger

Post in 2015
Avinger, Inc. is a medical device company focused on developing catheter-based technologies for the treatment of peripheral arterial disease (PAD). Founded in 2007 and headquartered in Redwood City, California, Avinger designs and manufactures image-guided systems that assist physicians in managing vascular diseases. Its product lineup includes the Lightbox imaging console and the Ocelot family of catheters, which facilitate penetration of total blockages in arteries, known as chronic total occlusions (CTOs). Additionally, the Pantheris device offers image-guided atherectomy, enabling precise removal of arterial plaque in PAD patients. Avinger markets its products to interventional cardiologists, vascular surgeons, and interventional radiologists across the United States and Europe.

ViewRay

Post in 2015
ViewRay, Inc. is a company that designs, manufactures, and markets advanced radiation therapy systems for cancer treatment. Its primary product, MRIdian, is an MRI-guided radiation therapy system that allows for simultaneous imaging and treatment of cancer patients. This innovative system integrates MRI technology, radiation delivery, and proprietary software to accurately locate and track soft-tissue tumors, enabling precise targeting while minimizing radiation exposure to surrounding healthy tissues. By providing real-time imaging during treatment, MRIdian addresses significant limitations of traditional radiation therapy methods, enhancing the safety and effectiveness of cancer treatment. ViewRay serves a diverse clientele, including university hospitals, community hospitals, private practices, government institutions, and independent cancer centers, primarily in the United States and internationally. The company was founded in 2004 and is headquartered in Oakwood, Ohio.

Outset Medical

Debt Financing in 2015
Outset Medical, Inc. is a medical technology company based in San Jose, California, focused on innovating hemodialysis systems. The company has developed Tablo, a compact dialysis machine designed for use in both acute and chronic care settings. This system integrates essential features such as water purification, on-demand dialysate production, and advanced software capabilities, including wireless data connectivity and sensor-based automation. By simplifying the dialysis process, Tablo aims to reduce costs and enhance the experience for both patients and healthcare providers. Founded in 2003 and originally named Home Dialysis Plus, Ltd., Outset Medical rebranded in 2015 to reflect its commitment to transforming dialysis care.

Ceterix Orthopaedics

Debt Financing in 2015
Ceterix Orthopaedics, Inc. is a medical technology company focused on developing innovative surgical tools for arthroscopic procedures. Based in Fremont, California, the company offers the Ceterix NovoStitch® Plus Meniscal Repair System, designed to repair various complex meniscal tears, including horizontal, radial, and root tears. Additionally, Ceterix provides the Novocut Suture Manager, a device that facilitates suture management during surgeries. The company's technology allows orthopedic surgeons to non-invasively create intricate suture patterns in tight joint compartments while safeguarding surrounding structures such as nerves and cartilage. Founded in 2010 by Dr. Justin Saliman, an orthopedic surgeon specializing in sports medicine, Ceterix aims to enhance the outcomes of arthroscopic procedures, addressing issues that often lead to untreated tears or the more invasive meniscectomy. As of January 2019, Ceterix operates as a subsidiary of Smith & Nephew plc.

TearLab

Post in 2015
TearLab Corporation develops and markets lab-on-a-chip technologies that enable eye care practitioners to improve standard of care by objectively and quantitatively testing for disease markers in tears at the point-of-care. The TearLab Osmolarity Test, for diagnosing Dry Eye Disease, is the first assay developed for the award winning TearLab Osmolarity System. Headquartered in San Diego, CA, TearLab Corporation's common shares trade on the NASDAQ Capital Market under the symbol TEAR and on the Toronto Stock Exchange under the symbol TLB.

Imaging Advantage

Debt Financing in 2015
Imaging Advantage is a prominent provider of technology-enhanced radiology solutions that focus on evidence-based practices for hospitals throughout the United States. The company offers innovative cloud-based technology designed to improve provider utilization and operational efficiency by integrating various information technology systems. Through the use of clinical and business algorithms, Imaging Advantage helps healthcare organizations optimize resource allocation, ensuring a better match between supply and demand within their networks. Its services are utilized by major healthcare systems in states including Arizona, California, Illinois, Michigan, Ohio, Oregon, and Texas, as well as in other significant metropolitan areas across the country.

Imaging Advantage

Private Equity Round in 2015
Imaging Advantage is a prominent provider of technology-enhanced radiology solutions that focus on evidence-based practices for hospitals throughout the United States. The company offers innovative cloud-based technology designed to improve provider utilization and operational efficiency by integrating various information technology systems. Through the use of clinical and business algorithms, Imaging Advantage helps healthcare organizations optimize resource allocation, ensuring a better match between supply and demand within their networks. Its services are utilized by major healthcare systems in states including Arizona, California, Illinois, Michigan, Ohio, Oregon, and Texas, as well as in other significant metropolitan areas across the country.

Blue Belt Technologies

Debt Financing in 2014
Blue Belt Technologies, Inc. focuses on the development and commercialization of robotics-assisted technologies designed for orthopedic surgery and other medical specialties. The company offers the Navio surgical system, which integrates intelligent handheld instruments with a CT-free registration and patient-specific planning process. Additionally, it provides the STRIDE unicondylar knee system for treating early-stage osteoarthritis in the knee, along with software applications that assist surgeons in planning knee replacements. These applications help in localizing implant components and balancing soft tissue. Beyond product offerings, Blue Belt Technologies also delivers support services, maintenance programs, and onsite training. Founded in 2003 and headquartered in Plymouth, Minnesota, Blue Belt Technologies became a subsidiary of Smith & Nephew in January 2016.

Nevro

Debt Financing in 2014
Nevro is a global medical device company dedicated to enhancing the quality of life for patients suffering from chronic pain. The company's primary product is the HFX spinal cord stimulation (SCS) platform, which features the Senza SCS system. This innovative neuromodulation system delivers Nevro's proprietary HF10 therapy, designed to provide effective pain relief through electrical impulses. The Senza system, which is implanted by physicians, includes essential components such as leads, a trial stimulator, an implantable pulse generator, surgical tools, a clinician laptop programmer, a patient remote control, and a mobile charger. Nevro primarily generates its revenue from the United States market, focusing on evidence-based solutions for chronic pain management.

Astute Medical

Debt Financing in 2014
Astute Medical is dedicated to improving the diagnosis of high-risk medical conditions and diseases through the identification and validation of protein biomarkers that can serve as the basis for novel diagnostic tests. The Company's focus is on community and hospital-acquired acute conditions that require rapid diagnosis and risk assessment. The company's current areas of interest include abdominal pain, acute coronary syndromes, cerebrovascular injury, kidney injury and sepsis. Founded in 2007, the company is led by Christopher Hibberd and Paul McPherson, former members of the management at Biosite Incorporated, a leading diagnostics company acquired by Inverness Medical Innovations in 2007 for $1.7 billion. Hibberd served at Biosite for 10 years, most recently as Senior Vice President Corporate Development. Dr. McPherson was at Biosite for 14 years, most recently as Vice President Research and Development.

Exagen

Debt Financing in 2014
Exagen Inc. is a diagnostics company focused on improving the care of patients with autoimmune diseases through the development and commercialization of innovative testing products under its AVISE brand. Utilizing its proprietary Cell-Bound Complement Activation Products technology, Exagen offers a range of tests aimed at the diagnosis, prognosis, and monitoring of complex autoimmune and autoimmune-related disorders, such as systemic lupus erythematosus and rheumatoid arthritis. Among its key products are AVISE CTD, which supports differential diagnosis for connective tissue diseases, and AVISE Lupus, which assesses complement system activation. The company's portfolio also includes AVISE APS for antiphospholipid syndrome, AVISE SLE Prognostic for risk assessment of complications, and tests for monitoring treatment efficacy in rheumatoid arthritis. Established in 2002 and headquartered in Vista, California, Exagen is dedicated to providing rheumatologists with timely and accurate diagnostic tools to enhance patient care.

AFT Pharmaceuticals

Debt Financing in 2014
AFT Pharmaceuticals Limited is a pharmaceutical company based in Auckland, New Zealand, specializing in the development, licensing, and sale of a wide range of medical products. Founded in 1997, the company offers approximately 130 prescription and non-prescription products across various therapeutic areas, including allergy, eye care, first aid, fungal treatments, pain management, skin care, and dietary supplements. AFT Pharmaceuticals operates across multiple regions, including New Zealand, Australia, Southeast Asia, and other international markets, with Australia being its primary source of revenue. The company is also involved in the distribution of its pharmaceutical products, contributing to its broad market presence.
NanoString Technologies, Inc. is a provider of life science tools focused on translational research and molecular diagnostics, headquartered in Seattle, Washington. Established in 2003, the company utilizes a unique digital molecular barcoding technology to create a range of products that facilitate gene expression analysis, microRNA studies, and copy number variation detection. Key offerings include the nCounter Analysis System, which consists of the nCounter MAX and FLEX systems, and the nCounter SPRINT Profiler, all designed for automated sample processing and data collection. The nSolver Analysis Software aids researchers in data normalization and analysis. Additionally, NanoString provides various custom CodeSets and panels tailored for specific applications, including cancer profiling and autoimmune disease research. The company is advancing the field of spatial genomics with its GeoMx Digital Spatial Profiler system and is developing the Hyb & Seq molecular profiling system for gene sequence analysis. NanoString collaborates with several pharmaceutical companies and research institutions to enhance its product offerings and expand its impact in the scientific community.

Biodesix

Debt Financing in 2014
Biodesix, Inc. is a diagnostic solutions company based in Boulder, Colorado, specializing in lung cancer diagnostics and biopharmaceutical services. The company offers a range of blood-based tests designed to assist physicians in evaluating the risk of malignancy in patients with suspicious lung nodules, including the Nodify XL2 and Nodify CDT tests. Additionally, it provides GeneStrat tumor profiling and VeriStrat immune profiling tests that enable more informed treatment decisions. Biodesix utilizes a proprietary mass spectrometry-based platform for the development of multivariate protein diagnostics, with its first product, VeriStrat, aiding oncologists in choosing between specific therapies for advanced lung cancer patients. The tests are processed in a CLIA-certified laboratory, with results delivered within 72 hours. Besides its diagnostic offerings, Biodesix collaborates with biopharmaceutical companies to develop companion diagnostics, enhancing the therapeutic effectiveness of various agents. Incorporated in 2005, Biodesix is committed to improving patient outcomes through innovative diagnostic solutions.

Solta Medical

Post in 2013
Solta Medical, Inc. is a developer and manufacturer of energy-based medical device systems focused on aesthetic applications. The company offers a range of products, including the Thermage NXT system for non-invasive skin tightening and body contouring, as well as the Fraxel series, which includes systems designed for skin resurfacing, rejuvenation, and treatment of various skin conditions such as acne scars and pigmentation issues. Their systems typically consist of handpieces, a user-friendly console, an energy source, and disposable treatment tips. Solta Medical's clientele includes dermatologists, plastic surgeons, and other medical professionals, and its products are marketed through a direct sales force and an international network of distributors. Founded in 1995 and headquartered in Hayward, California, the company previously operated under the name Thermage, Inc. before rebranding in 2009.

Exagen

Debt Financing in 2013
Exagen Inc. is a diagnostics company focused on improving the care of patients with autoimmune diseases through the development and commercialization of innovative testing products under its AVISE brand. Utilizing its proprietary Cell-Bound Complement Activation Products technology, Exagen offers a range of tests aimed at the diagnosis, prognosis, and monitoring of complex autoimmune and autoimmune-related disorders, such as systemic lupus erythematosus and rheumatoid arthritis. Among its key products are AVISE CTD, which supports differential diagnosis for connective tissue diseases, and AVISE Lupus, which assesses complement system activation. The company's portfolio also includes AVISE APS for antiphospholipid syndrome, AVISE SLE Prognostic for risk assessment of complications, and tests for monitoring treatment efficacy in rheumatoid arthritis. Established in 2002 and headquartered in Vista, California, Exagen is dedicated to providing rheumatologists with timely and accurate diagnostic tools to enhance patient care.

Exagen

Series D in 2013
Exagen Inc. is a diagnostics company focused on improving the care of patients with autoimmune diseases through the development and commercialization of innovative testing products under its AVISE brand. Utilizing its proprietary Cell-Bound Complement Activation Products technology, Exagen offers a range of tests aimed at the diagnosis, prognosis, and monitoring of complex autoimmune and autoimmune-related disorders, such as systemic lupus erythematosus and rheumatoid arthritis. Among its key products are AVISE CTD, which supports differential diagnosis for connective tissue diseases, and AVISE Lupus, which assesses complement system activation. The company's portfolio also includes AVISE APS for antiphospholipid syndrome, AVISE SLE Prognostic for risk assessment of complications, and tests for monitoring treatment efficacy in rheumatoid arthritis. Established in 2002 and headquartered in Vista, California, Exagen is dedicated to providing rheumatologists with timely and accurate diagnostic tools to enhance patient care.

RainDance Technologies

Debt Financing in 2013
RainDance Technologies, based in Billerica, Massachusetts, specializes in developing genomic tools for non-invasive liquid biopsy applications focused on the research, early detection, and treatment of cancer, as well as other inherited and infectious diseases. The company offers a range of innovative products, including the RainDrop digital polymerase chain reaction platform, which utilizes picoliter-sized droplets for multiplex detection of various genetic materials. Additionally, RainDance provides the ThunderStorm automated next-generation sequencing content enrichment solution, and the ThunderBolts NGS panels, designed for profiling significant cancer mutations and targeting genes associated with myeloid disorders. Through its advanced droplet technology, RainDance enables research institutions and laboratories to conduct precise genetic analysis, facilitating the understanding of complex genetic variations. Founded in 2004, the company operates as a subsidiary of Bio-Rad Laboratories and serves a global market through sales representatives and distributors.

Valeritas

Debt Financing in 2013
Valeritas Holdings, Inc. was a medical technology company focused on developing and commercializing innovative drug delivery solutions for patients with Type 2 diabetes. The company's primary product was the V-Go, a disposable insulin delivery device designed for continuous basal and on-demand bolus dosing, aimed at simplifying insulin management for users. Valeritas also worked on the V-Go Prefill, intended to streamline the device-filling process, and the V-Go SIM, which provided real-time tracking of insulin dosing. Founded in 2006 and headquartered in Bridgewater, New Jersey, Valeritas sold its products through third-party wholesalers and medical supply distributors. However, the company filed for Chapter 11 bankruptcy on June 30, 2020, ceasing operations.

Good Start Genetics

Debt Financing in 2013
Good Start Genetics, Inc. is a molecular diagnostics company based in Cambridge, Massachusetts, focused on genetic screening for inherited diseases. Founded in 2007, the company aims to transform reproductive medicine by providing physicians and patients with actionable insights into inherited genetic disorders. Good Start Genetics offers a range of services, including EmbryVu, a preimplantation genetic screening test designed to enhance in vitro fertilization outcomes by identifying suitable embryos for implantation. The company employs advanced next-generation DNA sequencing technology, along with other established genetic screening methods, to deliver high carrier detection rates. Additionally, through its GoodStart Select program, it provides a comprehensive menu of genetic carrier screening tests for both known and novel mutations, all supported by a commitment to customer care and genetic counseling. As of August 2017, Good Start Genetics operates as a subsidiary of Invitae Corporation.

TriVascular

Debt Financing in 2013
TRIVASCULAR is committed to developing new medical devices that address unmet clinical needs while providing an excellent working environment for its employees. The company was founded by Michael Chobotov, Ph.D., Robert Whirley, Ph.D., and Joseph Humphrey, Ph.D. TriVascular is located 50 miles north of San Francisco in the heart of the Sonoma Wine Country. TriVascular offers excellent career opportunities, benefits and quality of life to its employees. TRIVASCULAR's first products are next-generation transluminally placed endovascular grafts, often referred to as stent-grafts, for the treatment of aneurysmal disease in the abdominal aorta (AAA) and the thoracic aorta (TAA). Such endovascular procedures can lead to substantially lower mortality, morbidity, and cost compared to open surgical repair. TriVascular has developed a novel device design that achieves a low profile, permitting substantially improved access through the vasculature.

Tandem Diabetes Care

Debt Financing in 2013
Tandem Diabetes Care, Inc. is a medical device company that specializes in designing, developing, and marketing insulin delivery systems for individuals with insulin-dependent diabetes. Based in San Diego, California, the company’s flagship product is the t:slim X2 insulin delivery system, which includes a pump, a 300-unit disposable insulin cartridge, and an infusion set. The t:slim X2 is available with various advanced technologies, such as Basal-IQ and Control-IQ, and features like G5 integration. In addition to its insulin pumps, Tandem offers the t:connect web-based data management application and the Sugarmate mobile app to assist users in managing their diabetes. The company has also entered into a development and commercialization agreement with Dexcom, Inc. Tandem Diabetes Care has expanded its product line to include the smaller Mobi pump and is working on a tubeless insulin delivery system. The majority of its revenue comes from the U.S., with a smaller portion from other developed markets.

Corium

Convertible Note in 2012
Corium International, Inc. is a biopharmaceutical company based in Menlo Park, California, that specializes in the development, manufacture, and commercialization of specialty pharmaceutical products utilizing transdermal and transmucosal delivery systems. The company offers a range of products, including the Clonidine Transdermal Delivery System for hypertension, Fentanyl TDS for chronic pain management, and Crest Whitestrips for teeth whitening. Corium's pipeline includes Twirla, a hormonal contraceptive patch; MicroCor hPTH(1-34) for severe osteoporosis; and transdermal systems for Alzheimer's treatment, among others. Additionally, the company is advancing projects for psychiatric disorders and Parkinson's disease. Corium collaborates with several pharmaceutical companies, enhancing its research and development capabilities. The firm is recognized for its proprietary delivery technologies that improve therapeutic outcomes and safety profiles across various therapeutic areas.

Bioniche Pharma Group

Debt Financing in 2012
Bioniche Pharma Group manufactures and markets sterile injectable pharmaceutical products.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.